# Rise Therapeutics

Source: https://onco.cc/companies/rise-therapeutics/  
OnCo record `rise-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rise Therapeutics develops oral immune treatments. Its cancer medicine, R-5780, is a pill meant to help checkpoint immunotherapy work in tumours that have not responded to it, and it is in an early trial.

## Summary

Rise Therapeutics develops oral immunotherapies with its own oral delivery platform and in-house GMP manufacturing, for autoimmune disease and cancer. Its oncology product R-5780 is designed to enhance immune checkpoint inhibitor activity; the NIH RePORTER abstract describes it as based on secreted antigen A (SagA), an enzyme from Enterococcus faecium that engages microbiome-associated immune pathways. R-5780 is in a phase 1 trial with PD-1 inhibitors in solid tumours (NCT06398418). In fiscal year 2026 NCI awarded the company USD 740,140 under SBIR award 1R44CA306440-01A1 for clinical validation of R-5780.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Rise Therapeutics, LLC; Rise Therapeutics LLC
- HQ: Rockville, MD
- Type: biotech
- Website: https://risetherapeutics.com/

## Notes

- The website also lists autoimmune programmes, not recorded here. Read on risetherapeutics.com, ClinicalTrials.gov and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://risetherapeutics.com/
- Rise Therapeutics: pipeline: https://risetherapeutics.com/pipeline/
- NIH RePORTER: SBIR award 1R44CA306440-01A1: https://reporter.nih.gov/project-details/11399439

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Microbiome modulation to unlock immunotherapy](https://onco.cc/technologies/microbiome-modulation-io/)
- drugs: [R-5780](https://onco.cc/drugs/r-5780/)

---
JSON: https://onco.cc/api/v1/entities/rise-therapeutics.json